Related Experiment Videos
Calcium channel blockers and treatment of hypertension
Insights
Calcium channel blockers effectively manage essential hypertension, with benefits in specific patient groups. Further trials may establish them as a first-line treatment for hypertension.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Research explores the role of calcium ions in hypertension pathophysiology.
- Calcium channel blockers (CCBs) are investigated for managing essential hypertension.
Purpose of the Study:
- To review the efficacy and potential advantages of CCBs in hypertension management.
- To assess the role of CCBs in specific patient populations and refractory cases.
Main Methods:
- Review of numerous studies on CCBs like nifedipine, verapamil, and diltiazem.
- Analysis of blood pressure reduction, additive effects, and benefits in special populations.
Main Results:
- Nifedipine and verapamil are effective antihypertensive agents; diltiazem shows promise.
- Blood pressure reduction correlates with pre-treatment levels.
- CCBs offer advantages in elderly patients and those with comorbidities like ischemic heart disease, arrhythmias, and diabetes.
- Potential for reversing ventricular hypertrophy noted.
Conclusions:
- CCBs are effective antihypertensive agents with specific advantages.
- Combination therapy can enhance effects in refractory hypertension.
- Long-term safety data from clinical trials are needed to confirm first-line therapy status.
Abstract:
Over the past years, research efforts have been focused on the pathophysiologic role of calcium ions, and the implication for the potential role of calcium channel blockers in the management of essential hypertension. Numerous studies have shown that nifedipine and verapamil are effective antihypertensive agents, initial experience with diltiazem is also encouraging. The magnitude of blood pressure reduction with these drugs is related to the pre-treatment blood pressure. In refractory hypertension, combination with other antihypertensive agents provide additive effect. In the elderly population and in patients with ischemic heart disease, supraventricular arrhythmia, bronchospastic disease, peripheral vascular disease or diabetes mellitus, the calcium channel blockers offer potential advantages over other antihypertensive agents. Experimental studies also suggest that these drugs may reverse ventricular hypertrophy. When long-term safety with these drugs is documented from well-controlled clinical trials, the calcium channel blockers may be our first line of therapy for the management of hypertension.